Agrawal Prabhat, Gautam Ashish, Pursnani Nikhil, Maheshwari P K
Associate Professor, SN Medical College, Agra, Uttar Pradesh,Corresponding Author.
Associate Professor, SN Medical College, Agra, Uttar Pradesh.
J Assoc Physicians India. 2018 Aug;66(8):67-69.
Increasing diabetic burden worldwide is creating an alarming situation for the management and development of economic resources for it's treatment. Progressive nature of the disease requires allocation of a higher proportion of expenditure on health care initiative of any country.
Present study is designed with an aim to determine the effectiveness of cost-effective DPP-4 inhibitor, Teneligliptin, over the other agent of the same class.
The study was carried out in Postgraduate Department of Medicine, S.N. Medical College, Agra and 112 patients were selected as subjects with a selected inclusion criterion.
Independent student's t-test was applied to compare the means. Mean standard deviation was calculated for quantitative data. All p values were two-tailed and values p<0.05 were considered statistically significant.
There was no significant difference in the levels of blood sugar or glycosylated hemoglobin (HbA1c) before and after the treatment of Teneligliptin.
Teneligliptin offered an efficient second line treatment for the management of type-2 Diabetes Mellitus at a reduced average price of INR 39 per day, when compared to other DPP-4 inhibitors.
全球糖尿病负担的增加给糖尿病治疗的经济资源管理和发展带来了令人担忧的局面。该疾病的渐进性要求任何国家在医疗保健举措上分配更高比例的支出。
本研究旨在确定具有成本效益的二肽基肽酶-4（DPP-4）抑制剂替格列汀与同一类别的其他药物相比的有效性。
该研究在阿格拉S.N.医学院医学研究生部进行，112名患者根据选定的纳入标准被选为研究对象。
应用独立样本t检验比较均值。对定量数据计算均值标准差。所有p值为双侧，p<0.05的值被认为具有统计学意义。
替格列汀治疗前后血糖或糖化血红蛋白（HbA1c）水平无显著差异。
与其他DPP-4抑制剂相比，替格列汀以每天平均39印度卢比的较低价格为2型糖尿病的管理提供了有效的二线治疗。
